Neuromed Completes Enrollment For Phase 3 Chronic Low Back Pain Clinical Trial Of NMED-1077 Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain
drugs, announced it has completed enrollment in the pivotal Phase 3 chronic low back pain clinical trial of NMED-1077 (OROS(R) Hydromorphone) for the treatment of chronic moderate-to-severe pain in opioid tolerant patients.
Source: www.medicalnewstoday.comJazz Pharmaceuticals And UCB Announce Positive Phase III Results For Sodium Oxybate In Fibromyalgia Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and UCB (Euronext Brussels: UCB) announced today positive preliminary top-line results from the first of two Phase III clinical trials of sodium oxybate (JZP-6) for the treatment of fibromyalgia. The randomized, double-blind, placebo-controlled study achieved its key endpoints, demonstrating that sodium oxybate significantly decreased pain and fatigue, and improved daily function in patients with fibromyalgia.
Source: www.medicalnewstoday.comOrtho Biotech Announces NDA Submission For Trabectedin For The Treatment Of Relapsed Ovarian Cancer Ortho Biotech Products, L.P. announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection)for the treatment of women with relapsed ovarian cancer (ROC). If approved, trabectedin combined with DOXIL will provide a new, non-platinum treatment option for these patients in the United States.
Source: www.medicalnewstoday.comBush Administration 'Ignores Experts' On Proposed HHS Conscience Rule, Editorial Says Choosing to "ignore the experts," the Bush administration plans to move forward with a proposed HHS rule that allows
health care providers to opt out of care based on their moral or religious beliefs, a Pittsburgh Post-Gazette editorial says.
Source: www.medicalnewstoday.comStudy Improves Recovery For Mothers With Depression Scientists at the University of Liverpool have developed a therapy programme to treat depression in women in developing countries. Although depression is a major
health problem world-wide, experts say its impact is greatest in developing countries where 80% of the population live. Often there are no resources available to treat sufferers.
Source: www.medicalnewstoday.comSexually Harassed Employees Experience Less Job Satisfaction And Lower Job Performance A new study in the journal Psychology of Women Quarterly examined the effects of workplace sexual harassment and found that employees who were harassed report lower levels of job satisfaction, organizational commitment, and job performance. Employees also experienced higher levels of psychological distress and physical problems than those who were not harassed.
Source: www.medicalnewstoday.comEuropean Agency For The Evaluation Of Medicinal Products Recommends Suspension Of Marketing Authorisation For IONSYS(R) Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMEA) has recommended suspension of the marketing authorisation for IONSYS(R) (fentanyl iontophoretic transdermal system), indicated for the management of acute moderate to severe post-operative pain for use in a hospital setting only.
Source: www.medicalnewstoday.comAquarobics For Pregnant Women Makes For A Less Painful Delivery A course of water aerobics classes has been shown to reduce the amount of pain-killing medication women request during labor. Research published in BioMed Central's open access journal Reproductive
Health has shown that, as well as being safe, the gentle exercise has the benefit of making it easier to give birth.
Source: www.medicalnewstoday.com
# posted by Network @ 11:00 AM
